GlassScriptPhysician profile
Matthew Mignery
NPI 1912523259
$836.20
in general payments reported to CMS, 2019-2025
12 companies · $530 in 2025
The $530 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $306 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $598 · Education: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $598.02 |
| Education | $238.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $261.13 | 2024-2025 | Ensite, Assurity |
| Novartis Pharmaceuticals Corporation | $133.92 | 2024-2025 | |
| Lantheus Medical Imaging, INC. | $81.95 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $69.97 | 2024-2025 | Wainua |
| Pfizer INC. | $66.08 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $46.39 | 2025 | Onpattro |
| Kiniksa Pharmaceuticals International, Plc | $37.43 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $37.15 | 2024-2025 | Eliquis |
| Scpharmaceuticals INC. | $34.51 | 2024 | |
| Medtronic, INC. | $28.29 | 2024 | Azure Xt Dr Mri Surescan |
| Bayer Healthcare Pharmaceuticals INC. | $20.14 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $19.24 | 2025 | Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mignery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.